Your browser doesn't support javascript.
loading
Association between Reactogenicity and Immunogenicity in a Vaccinated Cohort with Two mRNA SARS-CoV-2 Vaccines at a High-Complexity Reference Hospital: A Post Hoc Analysis on Immunology Aspects of a Prospective Cohort Study.
Sáez-Peñataro, Joaquín; Calvo, Gonzalo; Bascuas, Juan; Mosquera, Maria Mar; Marcos, Maria Ángeles; Egri, Natalia; Torres, Ferran.
  • Sáez-Peñataro J; Medicines Division, Department of Clinical Pharmacology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain.
  • Calvo G; Medicines Division, Department of Clinical Pharmacology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain.
  • Bascuas J; Medicines Division, Department of Clinical Pharmacology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain.
  • Mosquera MM; Microbiology Department, Hospital Clinic, Institute for Global Health, University of Barcelona, 08036 Barcelona, Spain.
  • Marcos MÁ; Microbiology Department, Hospital Clinic, Institute for Global Health, University of Barcelona, 08036 Barcelona, Spain.
  • Egri N; CIBERINF, 28029 Madrid, Spain.
  • Torres F; Immunology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08007 Barcelona, Spain.
Vaccines (Basel) ; 12(6)2024 Jun 17.
Article en En | MEDLINE | ID: mdl-38932394
ABSTRACT
Enhancing our comprehension of mRNA vaccines may facilitate the future design of novel vaccines aimed at augmenting immune protection while minimising reactogenic responses. Before this design is carried out, it is important to determine whether adaptive immunity correlates with the reactogenicity profile of vaccines. We studied a large cohort that was vaccinated with mRNA vaccines to answer this question. This was an observational study with real-world data. Reactogenicity data were obtained from the VigilVacCOVID study. Immunogenicity (humoral and cellular) data were retrieved from health records. One main population (n = 215) and two subpopulations were defined (subpopulation 1, n = 3563; subpopulation 2, n = 597). Sensitivity analyses were performed with subpopulations 1 and 2 to explore the consistency of results. We analysed the association of the intensity and types of adverse reactions with the development and quantity of elicited antibody titres. As an exploratory analysis in subpopulation 1, we assessed the association between reactogenicity and cellular immunogenicity. A higher incidence of fever, malaise, and myalgia including severe cases was significantly associated with the development and quantity of positive antibody titres. No significant findings were observed with cellular immunity. We observed a positive association between immunogenicity and reactogenicity. These findings can be relevant for the future development of our understanding of how mRNA vaccines function.
Palabras clave